To assess the associations of semaglutide with incident AUD (first time diagnosis of AUD), the study population included 83,825 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new-user design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (naltrexone, topiramate, bupropion, orlistat, phentermine) 54 during 6/202112/2022 (time zero or index event), had no diagnosis of AUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
As more studies explore the optimal benefits of GLP-1 medications in heart disease, cognitive disorders, kidney health, and addiction, the scope of these medications is expanding beyond their original usage
Its similar to the GLOW product you showed earlier, but with one extra peptide and a different format
Plus, each territory and province has its own rules and regulations surrounding drug interchangeability
One of the benefits of having your journey guided by a comprehensive med spa is that we have solutions for your total transformation
